Sign in
Active, not recruitingPhase 4

A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD

Key facts

Who runs it
University of Pennsylvania
Where
Birmingham, Coatesville, Dallas, Menlo Park, Milwaukee, Philadelphia, and San Diego, United StatesSee the 7 sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
304 people enrolled
Started
25 May 2022
Ended
1 Nov 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Prolonged Exposure Therapy
  • Pharmacotherapy with paroxetine or venlafaxine XR
Record updated
9 June 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • DSM-5 diagnosis of Posttraumatic Stress Disorder
  • military veteran
  • fluent in English
  • willing to participate in PE, pharmacotherapy, or both
  • capable of providing informed consent

Who cannot take part

  • a failed trial of Prolonged Exposure therapy or paroxetine and venlafaxine XR
  • history of manic episode(s)
  • ongoing medical conditions or treatments that would contraindicate initiating these treatments (e.g., medications that have potential interactions with paroxetine and venlafaxine such as MAO inhibitors)
  • suicidal ideation with intent and/or plan, or suicidal behavior in the past month
  • active psychosis

Where in United States

  • Birmingham VA Healthcare SystemBirmingham, United States
  • Coatesville VA Medicial CenterCoatesville, United States
  • VA North Texas Healthcare SystemDallas, United States
  • VA Palo Alto Healthcare SystemMenlo Park, United States
  • Milwaukee VA Medical CenterMilwaukee, United States
  • Corporal Michael J. Crescenz VA Medical CenterPhiladelphia, United States
  • VA San Diego Healthcare SystemSan Diego, United States

About the trial

What the trial wants to find out

Posttraumatic Stress Disorder (PTSD) remains a salient and debilitating problem, in the general population and for military veterans in particular. Several psychological and pharmacological treatments for PTSD have evidence to support their efficacy. However, the lack of comparative effectiveness data for PTSD treatments remains a major gap in the literature, which limits conclusions that can be drawn about which of these treatments work best. The current study will compare the effectiveness of PTSD treatments with the strongest evidentiary support - Prolonged Exposure (PE) therapy and pharmacotherapy with paroxetine or venlafaxine - as well as the combination of these two treatments. A randomized trial will be conducted with a large, diverse sample of veterans with PTSD (N = 300) recruited from 6 VA Medical Centers throughout the US. Participants will complete baseline assessments, followed by an active treatment phase (involving up to 14 sessions of PE and/or medication management) with mid (7 week) and posttreatment (14 week) assessments, and follow-up assessments at 27 and 40 weeks. Study outcomes will include PTSD severity, depression, quality of life and functioning, assessed via clinical ratings and self-report measures. Further, a range of demographic and clinically relevant variables (e.g., trauma type/number, resilience) will be collected at baseline and examined as potential predictors or moderators of treatment response, addressing another gap in the PTSD treatment literature. These data will be used to develop algorithms from predicting the optimal treatment for individual patients (i.e., "personalized advantage indices"; PAIs). Effectiveness of the treatments will be compared using multilevel modeling. PAIs will be developed by conducting bootstrapped analyses to select variables that predict or moderate outcomes (clinician rated PTSD severity at Week 14), followed by jacknife analyses to determine the magnitude of the predicted difference (representing an individual's "predicted advantage" of one treatment over the others).

The 3 groups in the trial

  • Prolonged Exposure TherapyExisting treatment, for comparison

    8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders

  • PharmacotherapyExisting treatment, for comparison

    20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily

    Treatment: Pharmacotherapy with paroxetine or venlafaxine XR

  • Combined treatment (Prolonged Exposure and Pharmacotherapy)Existing treatment, for comparison

    8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders AND 20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily

    Treatment: Prolonged Exposure Therapy and Pharmacotherapy with paroxetine or venlafaxine XR

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD: What Works Best, and for Whom
Publications
Record updated
9 June 2026